Raised fourth fund, Schroder Ventures Asia Pacific Fund (“SVAPF”), with regional focus (US$498 million)
Acquired a significant shareholding in Orchid Chemicals & Pharmaceuticals Limited, another Indian generic pharmaceutical businesses
Acquired what was, at that time, the largest stake and effective control of South-East Asia’s largest healthcare player, Parkway Holdings